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CiprofibrateobesityHDL cholesteroltriglyceridesfibrates Abstract
Background: Hypertriglyceridemia in combination with low HDL cholesterol levels is a risk factor
for cardiovascular disease. Our objective was to evaluate the efficacy of ciprofibrate for the
treatment of this form of dyslipidemia and to identify factors associated with better treatment
response.
Methods: Multicenter, international, open-label study. Four hundred and thirty seven patients
were included. The plasma lipid levels at inclusion were fasting triglyceride concentrations between
1.6–3.9 mM/l and HDL cholesterol ≤ 1.05 mM/l for women and ≤ 0.9 mM/l for men. The LDL
cholesterol was below 4.2 mM/l. All patients received ciprofibrate 100 mg/d. Efficacy and safety
parameters were assessed at baseline and at the end of the treatment. The primary efficacy
parameter of the study was percentage change in triglycerides from baseline.
Results: After 4 months, plasma triglyceride concentrations were decreased by 44% (p < 0.001).
HDL cholesterol concentrations were increased by 10% (p < 0.001). Non-HDL cholesterol was
decreased by 19%. A greater HDL cholesterol response was observed in lean patients (body mass
index < 25 kg/m2) compared to the rest of the population (8.2 vs 19.7%, p < 0.001). In contrast,
cases with excess body weight had a larger decrease in non-HDL cholesterol levels (-20.8 vs -
10.8%, p < 0.001). There were no significant complications resulting from treatment with
ciprofibrate.
Conclusions: Ciprofibrate is efficacious for the correction of hypertriglyceridemia / low HDL
cholesterol. A greater decrease in non-HDL cholesterol was found among cases with excess body
weight. The mechanism of action of ciprofibrate may be influenced by the pathophysiology of the
disorder being treated.
Background
Hypertriglyceridemia in combination with abnormally
low concentrations of HDL cholesterol (High Density
Lipoprotein Cholesterol) is one of the most common and
atherogenic profiles of lipid metabolism [1]. In the PRO-
CAM study [2], the 6-year incidence of coronary events in
men aged between 40 and 60 years, was twelve times
higher than in the control group. The prevalence of this
abnormality varies among ethnic groups [3]. It is found in
13% of the Mexican adults living in urban areas [4]. It is
more common in men than in women (20.9% vs 7.2%)
and in some age groups (i.e. men aged 30 to 39 years) this
prevalence is as high as 30%. This lipid profile is the most
frequent form of dyslipidemia in the metabolic syndrome
[5]. However it is also found in subjects affected by pri-
mary dyslipidemias (e.g familial combined
hyperlipidemia).
In the Veteran Affairs HDL Intervention Trial (VAHIT), the
use of a fibrate (gemfibrozil) resulted in a 22% reduction
in the incidence of cardiovascular events in subjects with
low HDL cholesterol and a broad range of triglyceride val-
ues [6]. The benefit was accounted for by the positive
effects obtained in cases with insulin resistance [7]. In
spite of these positive results, there are few studies assess-
ing the efficacy of other fibrates in the treatment of this
form of dyslipidemia [8]. Relevant data such as the per-
centage of cases that achieve treatment goals are not
described in the majority of these reports. Also, variables
predicting a greater likelihood of achieving treatment
goals remain to be identified. Our objective was to assess
the efficacy and safety of ciprofibrate (100 mg/day) for the
treatment of cases with hypertriglyceridemia /
hypoalphalipoproteinemia in an open label, multicenter,
international study. A clinically oriented approach is used
for the description of the results.
Materials and Methods
The trial included men and post-menopausal or non-preg-
nant women aged between 30 and 70 years who had
hypertriglyceridemia (fasting concentrations between
1.68–3.9 mM/l (150 – 350 mg/dl) and hypoalphalipo-
proteinemia (HDL cholesterol ≤ 1.05 mM/l (40 mg/dl)
for women and ≤ 0.92 mM/l (35 mg/dl) for men). The
LDL cholesterol had to be lower than 4.2 mM/l (160 mg/
dl). Patients were excluded if they had an acute coronary
event during the three months preceding the study, type 1
diabetes, uncontrolled hypertension, severe renal dys-
function, nephrotic syndrome or aspartate aminotrans-
ferase (AST) or alanine aminotransferase (ALT) levels >
1.5 × the upper limit of normal (ULN), or if their creatine
phosphokinase (CPK) levels were > 3 × ULN. Consump-
tion of any lipid-altering drug within the previous 4 weeks
(6 months for probucol) prevented entry into the study.
Patients could be receiving other concomitant medication
as long as the dosage was not modified during the study.Cardiovascular Diabetology 2004, 3:8 http://www.cardiab.com/content/3/1/8
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The Ethics Committee in each institution approved the
protocol and every patient provided witnessed, written
informed consent prior to entering the study.
This was a multicenter, international, open-label study.
Patients were recruited from 25 lipid clinics from México
(n = 152), Brazil (n = 129), Chile (n = 78) and Colombia
(n = 78). Cases fulfilling the inclusion criteria were invited
to participate. The initial visit included a medical evalua-
tion, a physical examination and the prescription of an
isocaloric diet consisting of 50% carbohydrate, 30% fat,
20% protein with a cholesterol content of 200 mg [9].
Blood samples were obtained after a 9–12 h fasting
period. All patients were assigned to receive ciprofibrate
100 mg at bedtime. The second and final visit was sched-
uled 4 months later. During this visit drug compliance
and safety profile were assessed and body weight as well
as laboratory parameters were measured. Drug compli-
ance was measured by counting the returned pills. Adher-
ence to the diet was not assessed during the study
The primary efficacy parameter was the percentage change
in triglycerides from baseline. Secondary efficacy parame-
ters included the percentage change in total cholesterol,
HDL cholesterol and non-HDL cholesterol from baseline.
Non-HDL cholesterol was calculated by subtracting the
HDL cholesterol from the total cholesterol levels. In a post
hoc analysis, the percentage of cases that achieved the
treatment goals proposed by the ATP-III recommenda-
tions [10] on the final visit was also estimated.
At each visit, AST, ALT, fasting plasma glucose and CPK
levels were measured. Clinically relevant complications
were defined as either CPK > 5 × ULN accompanied by
muscle pain, tenderness or weakness or ALT or AST > 3 ×
ULN. Patients were excluded from the study if they devel-
oped severe hyperglycemia or any other significant com-
plication to treatment. Other reasons for premature
withdrawal were lack of compliance to the medication.
Cases were instructed to contact their physician in case of
any side effect.
All samples were analyzed in a central laboratory (Quest
laboratories). In Brazil, the local laboratory of every center
was used instead. Blood samples were taken after an over-
night fast (≥ 9 hours). Measurements were performed dur-
ing the first 24 hours after the blood was drawn; blood
samples were kept at 4°C until the analysis. All laboratory
analyses were performed with commercially available
standardized methods. Glucose was measured using the
glucose oxidase method. Total serum cholesterol and trig-
lycerides levels were measured using an enzymatic
method. HDL cholesterol levels were assessed using phos-
photungstic acid and Mg2+.
Statistical analysis was performed using SPSS for Win-
dows version 10. An intention to treat analysis was used.
Two sided ANOVA tests were used for assessing differ-
ences between groups for continuous variables. All cate-
gorical variables were analyzed using the chi squared test.
Multiple logistic regression models were constructed for
the identification of variables associated with the achieve-
ment of treatment goals.
Results
Four hundred thirty seven patients were included. The
clinical characteristics of the study subjects are shown in
table 1. Almost half of the population had a body mass
index between 25 and 30 kg/m2 (n = 221); an additional
32.5% were obese (n = 142) Diabetes was present in 125
subjects (28.7%).
Both evaluations were completed in every case. The med-
ication was stopped before the trial was completed by 117
subjects (26.7%). In the majority of cases this was not
related to side effects (see below). In addition, 46 cases
(10.5%) had poor compliance to the medication. The
body weight remained constant in all patients. The alco-
hol and tobacco consumption was not modified during
the study.
Ciprofibrate treatment and diet had a significant benefi-
cial effect on the lipid profile, as shown in table 2. After 4
months of treatment, plasma triglyceride concentrations
were decreased by 44% (p < 0.001). HDL cholesterol con-
centrations were increased by 10.1% (p < 0.001). Non-
HDL cholesterol was decreased by 19.2% (p < 0.001).
Total cholesterol was also favorably modified (-14.9%, p
< 0.001). In contrast, LDL cholesterol had a minor modi-
fication (-5.4%, p < 0.001). A significant decrease in fast-
ing glycemia was observed in both obese and diabetic
cases. This change was not found in lean subjects.
Table 1: Baseline characteristics of the patients included in study 
(n = 437)
Variable N = 437
Sex
Male (n(%)) 239 (54.7)
Female (n(%)) 198 (45.3)
Age (years)* 54.7 ± 12.1
Body mass index (kg/m2) 28.8 ± 4.6
Diabetes (n(%)) 125 (28.7)
Fasting plasma glucose (mM/l)* 5.2 ± 0.6
Family history of dyslipidemia (n(%)) 171 (39.2)
Coronary heart disease (n(%)) 196 (45)
Aspartate aminotranferase (mU/l) 23 ± 11
Alanine aminotransferase (mU/l) 26 ± 14
Data expressed as mean ± standard deviation. *To convert to mg/dl, 
multiply by 18Cardiovascular Diabetology 2004, 3:8 http://www.cardiab.com/content/3/1/8
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The achievement of treatment goals is the ultimate aim of
lipid-lowering therapy. Almost half of the cases had
reduced their triglyceride concentrations below 1.68 mM/
l (150 mg/dl) (n= 191(43.7%). HDL cholesterol levels
above 1.05 mM/l (40 mg/dl) were found in 51% of the
cases (n = 223). Also, a significant proportion of the sub-
jects (63.15%, n = 276) achieved the non-HDL cholesterol
goal 4.2 mM/l (< 160 mg/dl). The LDL cholesterol goal <
3.4 mM/l (< 130 mg/dl) was attained by 56.2 % (n = 246).
A full correction of the hypertrigliceridemia / low HDL
cholesterol occurred in 129 subjects (29.5%). Many of
them also had a non-HDL cholesterol level below 4.2
mM/l (160 mg/dl) (n = 101, 23.1%)
The lipid response during treatment differed between
cases with a body mass index above or below 25 kg/m2. As
is shown in figure 1, the percentage change in HDL cho-
lesterol was higher in lean subjects. In contrast, the non-
HDL cholesterol concentration had a significantly greater
reduction among subjects with excess body weight. Both
differences remained significant even after adjusting for
age and gender. The lipid profile did not differ between
these groups during the initial visit.
Patients with diabetes had moderate hyperglycemia dur-
ing the study. Their fasting glycemia was 7.7 ± 2.6 mM/l
(139 ± 47 mg/dl) at baseline. A small but statistically
significant decrease in glucose concentration was
observed at the end of the trial (5.7 ± 3 mM/l, 104 ± 54
mg/dl p < 0.001). At baseline, their lipid profile differed,
from the non-diabetic subjects, only with regards to
higher triglyceride concentrations (3.13 ± 0.97 vs 2.95 ±
0.66 mM/l, p < 0.001). The lipid response to ciprofibrate
and dietary treatment did not differ from that observed in
the whole group. Individuals with a family history of dys-
lipidemia (n = 171) had higher cholesterol, triglycerides
and LDL cholesterol at baseline compared to the rest of
the population. The lipid response to treatment was simi-
lar to that reported in the whole group.
Multiple regression models were constructed to identify
variables associated with the achievement of the treat-
ment goals. For every target value, the main determinants
were the baseline value and the percentage change after
treatment. No other parameter provided additional infor-
mation in any of the models. Thus, we analyzed the vari-
ables associated with the percentage change during
treatment. The non-HDL cholesterol model provided
more information compared to models derived from the
other lipid parameters. In the non-HDL cholesterol
model, a body mass index greater than 25 kg/m2, the trig-
lyceride response and the coexistence of cholesterol above
5.2 mM/l (200 mg/dl) (mixed hyperlipidemia) were pre-
dictors for a greater non-HDL cholesterol response (table
3). For both, the HDL cholesterol and the triglycerides
models, the inclusion of a body mass index < 25 kg/m2
added little information and had only borderline statisti-
cal significance. No other clinically relevant variable was
associated with the percentage change of any other lipid
parameter.
Table 2: Changes in the lipid profile and clinical characteristics between baseline and post-treatment values
Intention to treat analysis N = 437
Baseline Final Percent change
Triglycerides (mM/l) † 3.01 ± 0.7 1.61 ± 0.8 -44 ± 33*
HDL Cholesterol (mM/l)‡ 0.91 ± 0.1 0.98 ± 0.4 10 ± 52*
Non-HDL cholesterol (mM/l)‡ 4.57 ± 0.9 3.61 ± 1.5 -19 ± 36*
Cholesterol (mM/l)‡ 5.5 ± 0.9 4.57 ± 1.8 -14.9 ± 35*
LDL Cholesterol (mM/l)‡ 3.1 ± 0.9 2.8 ± 1.3 -5.4 ± 59*
Mean ± standard deviation are presented. *p < 0.001 †To convert to mg/dl multiple by 89 ‡To convert to mg/dl multiple by 38
The percentage of change in the lipid parameters is different  in cases with a body mass index above 25 kg/m2 compared to  the response observed in lean individuals during treatment  with ciprofibrate and diet Figure 1
The percentage of change in the lipid parameters is different 
in cases with a body mass index above 25 kg/m2 compared to 
the response observed in lean individuals during treatment 
with ciprofibrate and diet.
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Liver function tests were not modified by the treatment.
No patient had a significant alteration of any of the
laboratory tests. There were no incidents of either myopa-
thy or liver dysfunction. No persistent elevations in ALT,
AST or CPK, defined as clinically relevant, were reported
during the course of the study.
Discussion
The combination of hypertriglyceridemia / low HDL cho-
lesterol is a common abnormality of lipoprotein metabo-
lism and is associated with increased cardiovascular risk.
Our data show that ciprofibrate and an isocaloric diet are
an effective treatment for this dyslipidemia. However,
there was significant variation in response to treatment
between individuals. Excess body weight may be an
important determinant of the lipid response. It is associ-
ated with a greater degree of non-HDL cholesterol reduc-
tion and a relatively smaller elevation in HDL cholesterol.
A significant improvement in plasma triglycerides and
HDL cholesterol concentrations resulted from the admin-
istration of ciprofibrate and dietary modifications. Our
results are in agreement with previous studies [11-15].
This study differs from previous reports due to its design.
We wanted to assess the lipid response to ciprofibrate in a
real life environment. Hence, the highly controlled
conditions of a randomized, double blind study were
avoided. Also, we limited our inclusion criteria to subjects
with hypertriglyceridemia / low HDL cholesterol, instead
of including subjects with a wide variety of lipid profiles.
The results are in accordance with the uncontrolled design
of the study. By the use of ciprofibrate and isocaloric diet,
almost half of the cases achieved the triglyceride goal
(1.68 mM/l, 150 mg/dl). HDL cholesterol levels above 40
mg/dl were found in 51% of the cases. The full correction
of the combination of hypertriglyceridemia / low HDL
cholesterol occurred in a third of the population. This rate
is similar to that reported for the LDL cholesterol goals
achieved by the use of statins. Thus, our results reflect the
strengths and limitations of treating this lipid abnormal-
ity in an uncontrolled setting.
A large range of lipid responses was observed between
individuals. There are few reports designed to analyse the
determinants of the lipid response to fibrates. Robins
reported a lower HDL cholesterol elevation with a fibrate
when insulin resistance is present [7]. In this report, a
lower HDL cholesterol response was observed in patients
with excess body weight (body mass index above 25 kg/
m2) in comparison to that found in lean individuals.
Since excess body weight is strongly associated with insu-
lin resistance [16,17], our observations may be in agree-
ment with the findings of Robins. Interestingly, the
presence of insulin resistance was associated with the low-
est incidence of coronary events in the VAHIT study. In
our report, obese individual had a larger decrease in non-
HDL cholesterol levels. The greater response in non-HDL
cholesterol observed in our obese (and possibly insulin
resistant) subjects may be one possible explanation for
the greater benefit found in insulin resistant subjects dur-
ing the VAHIT study. Our data suggest that the mecha-
nism of action of ciprofibrate may be altered by the
pathophysiology of the disorder being treated. The same
phenomenon has been observed with the use of statins
[18,19]. The greater reduction in non-HDL cholesterol in
subjects with excess body weight could be explained by an
increased clearance of remnants, IDL and VLDL particles.
Ciprofibrate may enhance their clearance either by
decreasing the concentration of the apolipoprotein CIII
(an inhibitor of the lipolytic activity of the lipoprotein
lipase) [20-22] or by increasing the mass and activity of
lipoprotein lipase [23]. Genes encoding apolipoprotein
CIII and lipoprotein lipase contain a PPAR-alpha
response element; hence their expression may be modi-
fied during treatment with a fibrate [24]. Additional stud-
ies are needed to identify other possible determinants of
the lipid response to treatment with a fibrate.
Several limitations of the study must be recognized. The
uncontrolled design resulted in a relatively high rate of
drug discontinuation. However, this phenomenon is a
common finding in studies done in open populations
assessing the adherence to different lipid-lowering medi-
Table 3: Multiple regression model using as dependent variable percent of change in non-HDL cholesterol concentration
Variable Beta coefficient ± standard error p value
Constant 14.4 ± 2.6 < 0.001
BMI < 25 kg/m2 7.6 ± 3.6 0.036
Mixed hyperlipidemia 0.82 ± 0.2 0.003
Percent of change of triglycerides 0.68 ± 0.4 < 0.001
Correlation coefficient = 0.647, r2 = 0.419, p = 0.001 BMI, Body mass indexCardiovascular Diabetology 2004, 3:8 http://www.cardiab.com/content/3/1/8
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cations [25]. To overcome this limitation, an intention to
treat analysis was used. Also, the lack of a run-in period in
which the effect of diet could be measured and the
absence of information about the adherence to the diet
prevented us from discerning to what extent the observed
result was due to fibrate alone. Finally, some of the con-
clusions, like the identification of the determinants of the
lipid response, came from a post hoc analysis.
In conclusion, ciprofibrate is effective in the treatment of
patients with hypertriglyceridemia / low HDL cholesterol.
Significant reductions in triglycerides and non-HDL cho-
lesterol resulted from ciprofibrate therapy. In addition,
higher HDL cholesterol levels were found at the end of the
treatment. Excess body weight alters the lipid response to
ciprofibrate. A greater non-HDL cholesterol lowering is
achieved in subjects with excess body weight compared to
that found in lean individuals. Controlled trials are
needed to compare the lipid-lowering effects of ciprofi-
brate in groups of subjects defined by their adiposity or
other markers of insulin resistance.
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